Business
Taysha Gene Therapies Announces Pricing of Initial Public Offering
DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (“Taysha”), a patient-centric gene therapy company focused on developing and commercializing AAV-based
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":" DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (“Taysha”), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced the pricing of its initial public offering of 7,869,566 shares of common stock at a price to the public of $20.00 per share.\n\nThe shares are expected to begin trading on the Nasdaq Global Select Market under the symbol “TSHA” on September 24, 2020, and the offering is expected to close on September 28, 2020, subject to customary closing conditions. In addition, Taysha has granted the underwriters a 30-day option to purchase up to 1,180,434 additional shares of common stock at the initial public offering price less underwriting discounts and commissions.\n\nGoldman Sachs & Co. LLC, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering. Chardan is acting as lead manager for the offering.\n\nThe offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526 or by emailing [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or Jefferies, LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022 or by emailing [email protected].\n\nA registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\n\nForward-Looking Statements\n\nThis press release contains certain forward-looking statements, including statements with regard to Taysha’s proposed securities offering. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “anticipates,” and “fut...